Comment to: II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies. einstein (São Paulo). 2017;15(1):1-16

Dear editor,

We would like to update the readership of einstein (São Paulo) on the information given in page 6, regarding hyaluronidase facilitated subcutaneous immunoglobulin, in the article entitled II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies published in this journal in volume 15 issue 1, 2017.⁽¹⁾

When the article was written information available was that hyaluronidase facilitated subcutaneous immunoglobulin was not approved to be used by children and pregnant women, even in countries that the product is commercially available. However, in Europe the product is approved to be used by children of any age since July 2016.^(2–4) The hyaluronidase facilitated subcutaneous immunoglobulin infusion use in pregnant women, however, is still under investigation⁽⁴⁾

To correct this information is relevant because it guarantees that our article can provide the most accurate information as possible. In addition, patients should learn about the availability of this new therapeutic resource until this medication becomes approved in our country.

REFERENCES

• ¹
  Goudouris ES, Rego Silva AM, Ouricuri AL, Grumach AS, Condino-Neto A, Costa-Carvalho BT, Prando CC, Kokron CM, Vasconcelos DM, Tavares FS, Silva Segundo GR, Barreto IC, Dorna MB, Barros MA, Forte WC. II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies. einstein (São Paulo). 2017;15(1):1-16. Erratum in: einstein (São Paulo). 2017;15(3):387.
• ²
  PR Newswire. Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe [Internet]. ZUG: Switzerland; 2016. [cited 2017 Aug 9]. Available from: http://www.prnewswire.com/news-releases/shire-launches-pediatric-indication-for-immunodeficiency-treatment-hyqvia-in-europe-587772371.html
  » http://www.prnewswire.com/news-releases/shire-launches-pediatric-indication-for-immunodeficiency-treatment-hyqvia-in-europe-587772371.html
• ³
  European Medicines Agency (EMMA). Science Medicines Health [Internet]. London: England [cited 2017 Aug 9]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002491/WC500143851.pdf
  » http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002491/WC500143851.pdf
• ⁴
  European Medicines Agency (EMMA). Science Medicines Health [Internet]. London: England; 2013 [cited 2017 Aug 9]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002491/human_med_001647.jsp
  » http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002491/human_med_001647.jsp

Publication Dates

• Publication in this collection
  Oct-Dec 2017